info@marketresearchfuture.com   ๐Ÿ“ž  +1 (855) 661-4441(US)   ๐Ÿ“ž  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Prenatal Screening Tests Devices Market Research Report: Information By Test (Alpha-Fetoprotein (AFP) Tests, Free Beta Human Chorionic Gonadotropin (hCG) Tests, Inhibin A Tests, Non-invasive prenatal testing (NIPT), Pregnancy Associated Plasma Protein A (PAPP-A) Tests, Total Human Chorionic Gonadotropin (hCG) Tests, and Unconjugated Estriol (uE3) Tests), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) โ€“Market Forecast Till 2032


ID: MRFR/HC/14595-HCR | 128 Pages | Author: Rahul Gotadki| October 2024

Global Prenatal Screening Tests Devices Market Overview


Prenatal screening tests devices Market Size was valued at USD 0.72 Billion in 2022. The prenatal screening tests devices industry is projected to grow from USD 0.80 Billion in 2023 to USD 2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.00% during the forecast period (2023 - 2032). An increased understanding of the value of prenatal screening for the early identification of fetal abnormalities among pregnant parents and healthcare professionals are the key market drivers boosting the expansion of the market.


Prenatal Screening Tests Devices Market


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Prenatal screening tests devices Market Trends



  • Growing maternal age is driving the market growth


Market CAGR for prenatal screening tests devices is being driven by the Growing Maternal Age. Prenatal testing gives you details about the health of your unborn child. It finds any issues, including as genetic flaws and congenital disorders that might have an impact on the health of fetuses. While some women require specialized screening procedures, doctors advise certain prenatal screenings. Testing is done on newborns to find anomalies that may lead to inborn genetic disorders or other health issues. During screening, genetic disorders such as homocystinuria, phenylketonuria, and Down syndrome can be identified in neonates.


Additionally, the tendency to put off having children raises the risk of chromosomal abnormalities and genetic illnesses in babies. Prenatal screening tests to identify such anomalies are becoming more and more necessary as more women want to become pregnant at older ages. Growth in the industry is stimulated by increased healthcare spending, particularly in developed and emerging nations where it leads to better access to screening tests and prenatal care. However, due to high costs or inadequate healthcare infrastructure, access to advanced prenatal screening tests may be restricted in some areas or healthcare settings, which could have an impact on broad adoption.


A greater frequency of chromosomal abnormalities and genetic illnesses in babies is a result of the trend of postponing delivery. Prenatal screening tests are becoming more and more necessary to identify these anomalies as more women choose to become pregnant at older ages. Prenatal screening tests that don't involve risk are more frequently adopted because expectant parents are drawn to non-invasive, risk-free ways of keeping an eye on their unborn child's health. 


Prenatal screening tests are in high demand because early discovery of fetal anomalies enables better medical management and educates parents and healthcare providers in making decisions. For instance, the World Health Organization (WHO) estimates that congenital anomalies account for 6% of all births and are a major contributor to the  illness burden, particularly in low- and middle-income nations. Additionally, the Prenatal and Newborn Genetic Testing Market Size is positively impacted by the increase in demand for non-invasive prenatal screening. Thus, result in driving the prenatal screening tests devices market revenue.


Prenatal screening tests devices Market Segment Insights


Prenatal screening tests devices Test Insights


The  prenatal screening tests devices market segmentation, based on test includes Alpha-Fetoprotein (AFP) Tests, Free Beta Human Chorionic Gonadotropin (hCG) Tests, Inhibin A Tests, Non-invasive prenatal testing (NIPT), Pregnancy Associated Plasma Protein A (PAPP-A) Tests, Total Human Chorionic Gonadotropin (hCG) Tests, and Unconjugated Estriol (uE3) Tests. The non-invasive prenatal testing (NIPT) segment dominated the market. A blood test called NIPT is more precise than the initial pregnancy screening exam. It is provided to expectant mothers whose unborn child has been diagnosed with a higher probability of developing Down syndrome, Edwards’s syndrome, or Patau syndrome based on results from prior screening tests.


Figure1:  Prenatal screening tests devices Market, by Test, 2022&2032(USD Billion)


Prenatal screening tests devices Market, by Test, 2022&2032


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Prenatal screening tests devices Regional Insights


By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American prenatal screening tests devices market area will dominate this market. Newborns in North America are more likely to have chromosomal abnormalities and genetic illnesses as a result of the tendency of women delaying childbirth. As a result, older pregnant mothers are calling for prenatal screening tests more frequently.


Further, the major countries studied in the market report are The US, German, France, the UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil.


Figure2:  PRENATAL SCREENING TESTS DEVICES MARKET SHARE BY REGION 2022 (USD Billion)


PRENATAL SCREENING TESTS DEVICES MARKET SHARE BY REGION 2022


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Europe prenatal screening tests devices market has the second-largest portion of the market. Prenatal screening test uptake and general availability are supported by this infrastructure. Further, the German prenatal screening tests devices market held the largest proportion of the market, and the UK prenatal screening tests devices market was the European market with the quickest rate of growth.


The Asia-Pacific Prenatal screening tests devices Market has the quickest predicted compound annual growth rate (CAGR) between 2023 and 2032. Infrastructure improvements for healthcare, particularly in the region's fast developing economies. Moreover, China’s prenatal screening tests devices market had the biggest market share, and the Indian prenatal screening tests devices market was the Asia-Pacific region's fastest-growing market.


Prenatal screening tests devices Key Market Players& Competitive Insights


Leading market players are putting a lot of money on R&D to expand their product lines, which will drive the market for prenatal screening test devices to continue growing. Additionally, market players are engaging in a range of calculated initiatives to increase their worldwide presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To grow and endure in an increasingly cutthroat and dynamic market, prenatal screening tests devices industry must provide reasonably priced goods.


Manufacturing locally is one of the primary business techniques used by manufacturers to cut operational costs in the  prenatal screening tests devices industry to help customers and expand the market segment. In recent years, the prenatal screening tests devices industry has provided some of the biggest benefits to medicine. Major players in the prenatal screening tests devices market, including Illumina Inc, BGI Genomics Co Ltd, Yourgene Health Plc, Eurofins Scientific SE, Agilent Technologies Inc, Roche Diagnostics International Ltd, PerkinElmer Inc, Beckman Coulter Inc., and others, are engaging in research and development activities in an effort to boost market demand.


Illumina creates and sells integrated solutions for biological function and genetic variation analysis. Illumina recorded revenue growth of about 6% in 2019. The business put forth an acquisition proposal for Pacific Biosciences that same year for $8.00 per share, or about $1.2 billion. Illumina revealed in 2020 that it will pay $8 billion in cash and stock to purchase Grail. The goal of Illumina's iHope Genetic Health program, which was launched in 2021 in partnership with Genetic Alliance, is to give low- and middle-income populations affected by genetic disease access to whole genome sequencing.


BGI Genomics is a Chinese genomics company that offers genomic testing and research services to medical organizations, research institutes, businesses, and public agencies. The functional microbiome analyses were made possible by the publication of 1,520 reference genomes from farmed human gut bacteria by BGI Genomics in 2019. Using its in-house DNBSEQ TM technology platform, BGI has been offering a rapid whole genome sequencing (rWGS) service since 2019. This service is designed to expedite the processing of massive sequencing data. A BGI subsidiary, Forensic Genomics International, developed a nationwide genetic profile database that was compatible with WeChat in the same year.


Key Companies in the Prenatal Screening Tests Devices Market Include



  • Illumina Inc

  • BGI Genomics Co Ltd

  • Yourgene Health Plc

  • Eurofins Scientific SE

  • Agilent Technologies Inc

  • Roche Diagnostics International Ltd

  • PerkinElmer Inc

  • Beckman Coulter Inc

  • Abbott Laboratories

  • Siemens Healthineers AG

  • Quidel Corp

  • Thermo Fisher Scientific Inc

  • Tosoh Corp


Prenatal screening tests devices Industry Developments


October 2022:Eurofins commissioned a study that revealed the company has delivered a total shareholder return of about 36,600% since its IPO.


August 2020:Agilent announced the expansion of its cutting-edge production facility in Frederick, Colorado, which is responsible for the development and production of "oligos," which are small molecules of DNA and RNA that are utilized to produce therapies based on nucleic acids.


January 2023:Agilent revealed plans to expand its life science plant in Frederick, Colorado, for $725 million. With this move, the company will be able to increase its manufacturing capacity at the property located outside of Denver.


Prenatal screening tests devices Market Segmentation


Prenatal screening tests devices Test Outlook



  • Alpha-Fetoprotein (AFP) Tests

  • Free Beta Human Chorionic Gonadotropin (hCG) Tests

  • Inhibin A Tests

  • Non-invasive prenatal testing (NIPT)

  • Pregnancy Associated Plasma Protein A (PAPP-A) Tests

  • Total Human Chorionic Gonadotropin (hCG) Tests

  • Unconjugated Estriol (uE3) Tests


Prenatal screening tests devices Regional Outlook



  • North America

    • US

    • Canada



  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Australia

    • Rest of Asia-Pacific



  • Rest of the World

    • Middle East

    • Africa

    • Latin America



Report Attribute/Metric Details
Market Size2022 USD 0.7 Billion
Market Size 2023 USD 0.8 Billion
Market Size2032 USD 2 Billion
Compound Annual Growth Rate (CAGR) 12.00% (2023-2032)
Base Year 2022
Market Forecast Period 2023-2032
Historical Data 2018- 2022
Market Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered Test, and Region
Geographies Covered North America, Europe, AsiaPacific, and the Rest of the World
Countries Covered The US, German, France, UK, Canada, Italy, Spain, India, Australia, South Korea, China, Japan, and Brazil
Key Companies Profiled ย Illumina Inc, BGI Genomics Co Ltd, Yourgene Health Plc, Eurofins Scientific SE, Agilent Technologies Inc, Roche Diagnostics International Ltd, PerkinElmer Inc, Beckman Coulter Inc.,
Key Market Opportunities ยทย ย ย ย ย ย ย ย  Market penetration may be impacted by disparities in reimbursement laws among various geographic areas.
Key Market Dynamics ยทย ย ย ย ย ย ย ย  It is essential to guarantee the clinical validity and precision of prenatal screening tests.


Frequently Asked Questions (FAQ) :

In 2022, the prenatal screening test devices market was estimated to be worth USD 0.7 billion ly.

From 2023 to 2032, Around 12.00%(CAGR) is anticipated for the

North America held the most market share worldwide.

The leading companies in the market are Beckman Coulter Inc., Roche Diagnostics International Ltd., Agilent Technologies Inc., Illumina Inc., BGI Genomics Co Ltd., Yourgene Health Plc, and Eurofins Scientific SE.

In 2022, the market was led by the non-invasive prenatal testing (NIPT) category.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.